The therapeutic regimen is finally driven by the characterization of the breast cancer subtype according to the immunohistochemical evaluation of three markers: Estrogen receptor (ER), Progesteron Receptor (Pgr) and HER2 (Epidermal Growth Factor Receptor 2) [8]. Here, PGR is linked to breast carcinoma.